- call +1-201-465-4211
- email sales@mrinsights.biz
Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems.
Scope of the Report:
This report studies the Multiple Sclerosis market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Multiple Sclerosis market by product type and applications/end industries.
Nevertheless, the leading pharmaceutical companies operating in North America and Europe is shifting the focus on Asia-pacific region due to the growing demand for effective and economic MS treatment. . Pharmaceutical companies belong to developed regions are focusing on the commercialization of novel therapeutics having minimal side effects and economic pricing. Such product launch strategy would provide an opportunity for the pharmaceutical companies across developing economies. Furthermore, the market is majorly supplemented by increasing funding from government authorities for research and development.
The global Multiple Sclerosis market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Multiple Sclerosis.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbvie
Acorda Therapeutics
Bayer HealthCare
Biogen
Genzyme (Sanofi)
GlaxoSmithKline
Merck Serono
Novartis
Pfizer
Teva
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Injectable agents
Oral agents
Market Segment by Applications, can be divided into
Hosptial
Research
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Multiple Sclerosis Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis
1.2 Classification of Multiple Sclerosis by Types
1.2.1 Global Multiple Sclerosis Revenue Comparison by Types (2017-2023)
1.2.2 Global Multiple Sclerosis Revenue Market Share by Types in 2017
1.2.3 Injectable agents
1.2.4 Oral agents
1.3 Global Multiple Sclerosis Market by Application
1.3.1 Global Multiple Sclerosis Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hosptial
1.3.3 Research
1.4 Global Multiple Sclerosis Market by Regions
1.4.1 Global Multiple Sclerosis Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Multiple Sclerosis Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Multiple Sclerosis Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Multiple Sclerosis Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Multiple Sclerosis Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Multiple Sclerosis Status and Prospect (2013-2023)
1.5 Global Market Size of Multiple Sclerosis (2013-2023)
2 Manufacturers Profiles
2.1 Abbvie
2.1.1 Business Overview
2.1.2 Multiple Sclerosis Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbvie Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.2 Acorda Therapeutics
2.2.1 Business Overview
2.2.2 Multiple Sclerosis Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Acorda Therapeutics Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer HealthCare
2.3.1 Business Overview
2.3.2 Multiple Sclerosis Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer HealthCare Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biogen
2.4.1 Business Overview
2.4.2 Multiple Sclerosis Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biogen Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.5 Genzyme (Sanofi)
2.5.1 Business Overview
2.5.2 Multiple Sclerosis Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Genzyme (Sanofi) Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline
2.6.1 Business Overview
2.6.2 Multiple Sclerosis Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck Serono
2.7.1 Business Overview
2.7.2 Multiple Sclerosis Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck Serono Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.8 Novartis
2.8.1 Business Overview
2.8.2 Multiple Sclerosis Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Novartis Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.9 Pfizer
2.9.1 Business Overview
2.9.2 Multiple Sclerosis Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Pfizer Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
2.10 Teva
2.10.1 Business Overview
2.10.2 Multiple Sclerosis Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Multiple Sclerosis Revenue, Gross Margin and Market Share (2016-2017)
3 Global Multiple Sclerosis Market Competition, by Players
3.1 Global Multiple Sclerosis Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Multiple Sclerosis Players Market Share
3.2.2 Top 10 Multiple Sclerosis Players Market Share
3.3 Market Competition Trend
4 Global Multiple Sclerosis Market Size by Regions
4.1 Global Multiple Sclerosis Revenue and Market Share by Regions
4.2 North America Multiple Sclerosis Revenue and Growth Rate (2013-2018)
4.3 Europe Multiple Sclerosis Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Multiple Sclerosis Revenue and Growth Rate (2013-2018)
4.5 South America Multiple Sclerosis Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Multiple Sclerosis Revenue and Growth Rate (2013-2018)
5 North America Multiple Sclerosis Revenue by Countries
5.1 North America Multiple Sclerosis Revenue by Countries (2013-2018)
5.2 USA Multiple Sclerosis Revenue and Growth Rate (2013-2018)
5.3 Canada Multiple Sclerosis Revenue and Growth Rate (2013-2018)
5.4 Mexico Multiple Sclerosis Revenue and Growth Rate (2013-2018)
6 Europe Multiple Sclerosis Revenue by Countries
6.1 Europe Multiple Sclerosis Revenue by Countries (2013-2018)
6.2 Germany Multiple Sclerosis Revenue and Growth Rate (2013-2018)
6.3 UK Multiple Sclerosis Revenue and Growth Rate (2013-2018)
6.4 France Multiple Sclerosis Revenue and Growth Rate (2013-2018)
6.5 Russia Multiple Sclerosis Revenue and Growth Rate (2013-2018)
6.6 Italy Multiple Sclerosis Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Multiple Sclerosis Revenue by Countries
7.1 Asia-Pacific Multiple Sclerosis Revenue by Countries (2013-2018)
7.2 China Multiple Sclerosis Revenue and Growth Rate (2013-2018)
7.3 Japan Multiple Sclerosis Revenue and Growth Rate (2013-2018)
7.4 Korea Multiple Sclerosis Revenue and Growth Rate (2013-2018)
7.5 India Multiple Sclerosis Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Multiple Sclerosis Revenue and Growth Rate (2013-2018)
8 South America Multiple Sclerosis Revenue by Countries
8.1 South America Multiple Sclerosis Revenue by Countries (2013-2018)
8.2 Brazil Multiple Sclerosis Revenue and Growth Rate (2013-2018)
8.3 Argentina Multiple Sclerosis Revenue and Growth Rate (2013-2018)
8.4 Colombia Multiple Sclerosis Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Multiple Sclerosis by Countries
9.1 Middle East and Africa Multiple Sclerosis Revenue by Countries (2013-2018)
9.2 Saudi Arabia Multiple Sclerosis Revenue and Growth Rate (2013-2018)
9.3 UAE Multiple Sclerosis Revenue and Growth Rate (2013-2018)
9.4 Egypt Multiple Sclerosis Revenue and Growth Rate (2013-2018)
9.5 Nigeria Multiple Sclerosis Revenue and Growth Rate (2013-2018)
9.6 South Africa Multiple Sclerosis Revenue and Growth Rate (2013-2018)
10 Global Multiple Sclerosis Market Segment by Type
10.1 Global Multiple Sclerosis Revenue and Market Share by Type (2013-2018)
10.2 Global Multiple Sclerosis Market Forecast by Type (2018-2023)
10.3 Injectable agents Revenue Growth Rate (2013-2023)
10.4 Oral agents Revenue Growth Rate (2013-2023)
11 Global Multiple Sclerosis Market Segment by Application
11.1 Global Multiple Sclerosis Revenue Market Share by Application (2013-2018)
11.2 Multiple Sclerosis Market Forecast by Application (2018-2023)
11.3 Hosptial Revenue Growth (2013-2018)
11.4 Research Revenue Growth (2013-2018)
12 Global Multiple Sclerosis Market Size Forecast (2018-2023)
12.1 Global Multiple Sclerosis Market Size Forecast (2018-2023)
12.2 Global Multiple Sclerosis Market Forecast by Regions (2018-2023)
12.3 North America Multiple Sclerosis Revenue Market Forecast (2018-2023)
12.4 Europe Multiple Sclerosis Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Multiple Sclerosis Revenue Market Forecast (2018-2023)
12.6 South America Multiple Sclerosis Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Multiple Sclerosis Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Multiple Sclerosis Picture
Table Product Specifications of Multiple Sclerosis
Table Global Multiple Sclerosis and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
